Live Breaking News & Updates on Cognitive Function Items|Page 1

Stay updated with breaking news from Cognitive function items. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo AXS-12 achieved statistically significant remission of cataplexy compared to placebo AXS-12 statistically. ....

New York , United States , Mark Jacobson , Darren Opland , Michael Thorpy , Axsome Therapeutics Inc , Wake Disorders Center , Corporate Communications , Drug Administration , World Trade Center , Montefiore Medical Center , Cognitive Function , Sleep Wake Disorders Center , Albert Einstein College , Clinician Global Impression , Narcolepsy Symptom Assessment Questionnaire , Epworth Sleepiness Scale , Cognitive Function Items , Functional Outcomes , Sleep Questionnaire , Topline Results , Excessive Daytime Sleepiness , Narcolepsy Overall , Study Evaluating , Mechanistic Approach , Treating Narcolepsy ,

AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial

Axsome Therapeutics announced topline trial results, which show AXS-12 significantly improves key narcolepsy symptoms. ....

Michael Thorpy , Herriot Tabuteau , Albert Einstein College Of Medicine , Montefiore Medical Center , Wake Disorders Center , Axsome Therapeutics , Axsome Therapeutic , Clinician Global Impression , Narcolepsy Symptom Assessment , Epworth Sleepiness Scale , Cognitive Function Items , Functional Outcomes , Sleep Questionnaire , Sleep Wake Disorders Center , Albert Einstein College ,